New clinical data on tasquinimod in multiple myeloma to be presented at ASCO 2023

Lund, April 27 2023 – Active Biotech (NASDAQ Stockholm:ACTI) announces today that new data from the ongoing study with tasquinimod, a small molecule immunomodulator, in multiple myeloma will be presented in a poster session at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago, 2-6 June, 2023.

The poster will present interim results of safety and preliminary activity in the phase 1b dose escalation trial of tasquinimod as single agent and tasquinimod in combination with ixazomib, lenalidomide and dexamethasone (IRd) in patients with relapsed or refractory multiple myeloma. The study (NCT04405167) is conducted at Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. Abstracts will be released on May 25 at 5:00 PM (ET).

Details on the presentation:

  • Abstract Title: Phase 1 study of tasquinimod, an S100A9 inhibitor, alone and in combination with IRd for relapsed and refractory multiple myeloma (RRMM)
  • Session Title: Hematologic Malignancies – Plasma Cell Dyscrasia
  • Abstract Number: 8042
  • Session Date and Time: June 5, 2023, 8:00 AM-11:00 AM (ET)